Cipla's Regulatory Crisis: License Cancellation and Compliance Challenges
The Maharashtra FDA's cancellation of Cipla Pharma & Life Sciences Ltd's wholesale drug sales license at its Wadki warehouse over Reactin Plus misbranding and storage violations reveals critical compliance gaps. With minimal financial impact but significant reputational risks, Cipla navigates legal challenges while working to restore operations and stakeholder confidence.




















































